Treatment of familial hypercholesterolemia and other genetic dyslipidemias

Current Treatment Options in Cardiovascular Medicine

Volumn 6, Issue 4, 2004, Pages 269-278

  Dujovne, Carlos A ^a  

^a Kansas Found Clin Pharmacol Thera   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BILE ACID; CARBOHYDRATE; CHOLESTEROL; ERYTHROMYCIN DERIVATIVE; EZETIMIBE; FAT; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PHYTOSTEROL; PLACEBO; PRAVASTATIN; PYRROLE DERIVATIVE; ROSUVASTATIN; SIMVASTATIN; STANOL ESTER; UNINDEXED DRUG; URIC ACID;

ACANTHOSIS NIGRICANS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMBLYOPIA; AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CARBOHYDRATE DIET; CARDIOVASCULAR RISK; CHILD CARE; CHOLELITHIASIS; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG ALCOHOL INTERACTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG USE; DRY SKIN; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FLUSHING; FOOD DRUG INTERACTION; GASTRITIS; GENE EXPRESSION; GENETIC DISORDER; GENETIC VARIABILITY; GOUT; GRAPE JUICE; HEALTH EDUCATION; HEALTH PROGRAM; HEART ARRHYTHMIA; HEPATITIS; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPOTENSION; INHERITANCE; INTESTINE ANASTOMOSIS; KINESIOTHERAPY; LIFESTYLE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIVER TOXICITY; LIVER TRANSPLANTATION; LOW FAT DIET; MYOPATHY; MYOSITIS; OBESITY; PANCREATITIS; PHENOTYPE; PLASMAPHERESIS; PRACTICE GUIDELINE; PRURITUS; REVIEW; SECONDARY PREVENTION; SIDE EFFECT; SYNCOPE; TACHYPHYLAXIS; TREATMENT FAILURE; TREATMENT PLANNING; URIC ACID BLOOD LEVEL;

EID: 4344567142     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-004-0029-0     Document Type: Review

References (15)

1. Brown MS. Goldstein JL.: A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232:34-47.
2. Scanu AM: Lp(a) Lipoprotein-coping with heterogeneity. N Engl J Med 2003, 349:2089-2091.
3. Stone NJ, Blum CB, eds: Management of Lipids in Clinical Practice, edn 4. Caddo, OK: Professional Communications 2002.
4. Fredrickson DS: Dyslipoproteinemia from phenotypes to genotypes - a remarkable quarter century. Circulation 1993, 87(suppl 3):S1-S59.
5. Executive Summary of the Third Report of the National Cholesterol Education program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) [no authors listed]. JAMA 2001, 285:2486-2497.
6. Kwiterovich PO: Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol 2002, 90(suppl):30i-47i.
7. Bersot TP, Palaoglu KE, Mhley RW: Managing dyslipidemia in Turkey: suggested guidelines for a population characterized by low levels of-high-density lipoprotein cholesterol. Anadolu Kardiyol Derg 2002, 2:315-122.
8. Ballantyne CM: Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the Heart protection Study on standards of efficacy and safety. Am J Cardiol 2003, 92(suppl): 3K-9K.
9. Bays H, Dujovne CA: Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother 2003, 4:779-790.
10. Dujovne CA, Ettinger MP, McNeer F, et al.: Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002, 90:1092-1097.
11. Stein EA, Davidson MH, Dujovne GA, et al.: Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trial. J Cardiovasc Pharmacol Ther 1996, 1:107-116.
12. Gagné C, Caudet D, Bruckert E: Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002, 105:2469-2475.
13. Stein EA, Illingworth DR, Kwiterovich PO Jr, et al.: Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 1999, 281:137-144.
14. Bays HE, McKenney JM, Dujovne CA, et al.: Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol. Am J Cardiol 2003, 92:538-543.
15. Nissen SE, Tsunoda T, Tuzoa EM, et al.: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. JAMA 2003, 290:2292-2300.f